Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000803611 | SCV000943491 | likely benign | Nemaline myopathy 2 | 2023-12-07 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001766668 | SCV001999535 | uncertain significance | not provided | 2019-12-04 | criteria provided, single submitter | clinical testing | Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV002534757 | SCV003625961 | uncertain significance | Inborn genetic diseases | 2022-06-29 | criteria provided, single submitter | clinical testing | The c.18989G>A (p.R6330H) alteration is located in exon 142 (coding exon 140) of the NEB gene. This alteration results from a G to A substitution at nucleotide position 18989, causing the arginine (R) at amino acid position 6330 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV001766668 | SCV003809632 | uncertain significance | not provided | 2023-10-30 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003330959 | SCV004039266 | uncertain significance | not specified | 2023-08-03 | criteria provided, single submitter | clinical testing | Variant summary: NEB c.24662G>A (p.Arg8221His) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 2.1e-05 in 239754 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.24662G>A in individuals affected with Nemaline Myopathy 2 and no experimental evidence demonstrating its impact on protein function have been reported. Five ClinVar submitters have assessed the variant since 2014: four classified the variant as uncertain significance and one as likely benign. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Natera, |
RCV000803611 | SCV002083958 | uncertain significance | Nemaline myopathy 2 | 2020-08-07 | no assertion criteria provided | clinical testing |